Blocking integrin β1 decreases adhesion in chemoresistant urothelial cancer cell lines

  • Authors:
    • Stefan Vallo
    • Jochen Rutz
    • Miriam Kautsch
    • Ria Winkelmann
    • Martin Michaelis
    • Felix Wezel
    • Georg Bartsch
    • Axel Haferkamp
    • Florian Rothweiler
    • Roman A. Blaheta
    • Jindrich Cinatl Jr
  • View Affiliations

  • Published online on: September 4, 2017     https://doi.org/10.3892/ol.2017.6883
  • Pages: 5513-5518
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Treatment failure in metastatic bladder cancer is commonly caused by acquisition of resistance to chemotherapy in association with tumor progression. Since alterations of integrins can influence the adhesive and invasive behaviors of urothelial bladder cancer cell lines, the present study aimed to evaluate the role of integrins in bladder cancer cells with acquired resistance to standard first‑line chemotherapy with gemcitabine, and cisplatin. Therefore, four gemcitabine‑ and four cisplatin‑resistant sublines out of a panel of four parental urothelial bladder cancer cell lines (TCC‑SUP, HT1376, T24, and 5637) were used. Expression of integrin subunits α3, α5, α6, β1, β3, and β4 was detected using flow cytometry. Adhesion and chemotaxis were analyzed. For functional assays, integrin β1 was attenuated with a blocking antibody. In untreated cells, chemotaxis was upregulated in 3/4 gemcitabine‑resistant sublines. In cisplatin‑resistant cells, chemotaxis was enhanced in 2/4 cell lines. Acquired chemoresistance induced the upregulation of integrin β1 in all four tested gemcitabine‑resistant sublines, as well as an upregulation in 3/4 cisplatin‑resistant sublines compared with parental cell lines. Following the inhibition of integrin β1, adhesion to extracellular matrix components was downregulated in 3/4 gemcitabine‑resistant sublines and in all four tested cisplatin‑resistant sublines. Since integrin β1 is frequently upregulated in chemoresistant urothelial cancer cell lines and inhibition of integrin β1 may influence adhesion, further studies are warranted to evaluate integrin β1 as a potential therapeutic target for bladder cancer in vivo.
View Figures
View References

Related Articles

Journal Cover

November 2017
Volume 14 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Vallo, S., Rutz, J., Kautsch, M., Winkelmann, R., Michaelis, M., Wezel, F. ... Cinatl Jr, J. (2017). Blocking integrin β1 decreases adhesion in chemoresistant urothelial cancer cell lines. Oncology Letters, 14, 5513-5518. https://doi.org/10.3892/ol.2017.6883
MLA
Vallo, S., Rutz, J., Kautsch, M., Winkelmann, R., Michaelis, M., Wezel, F., Bartsch, G., Haferkamp, A., Rothweiler, F., Blaheta, R. A., Cinatl Jr, J."Blocking integrin β1 decreases adhesion in chemoresistant urothelial cancer cell lines". Oncology Letters 14.5 (2017): 5513-5518.
Chicago
Vallo, S., Rutz, J., Kautsch, M., Winkelmann, R., Michaelis, M., Wezel, F., Bartsch, G., Haferkamp, A., Rothweiler, F., Blaheta, R. A., Cinatl Jr, J."Blocking integrin β1 decreases adhesion in chemoresistant urothelial cancer cell lines". Oncology Letters 14, no. 5 (2017): 5513-5518. https://doi.org/10.3892/ol.2017.6883